Regular PaperRisk factors in primary sclerosing cholangitis
References (20)
- et al.
Primary sclerosing cholangitis. A study of forty-two cases
Am J Surg
(1966) - et al.
Improved survival in primary sclerosing cholangitis
Gastroenterology
(1987) - et al.
Natural history and prognostic variables in primary sclerosing cholangitis
Gastroenterology
(1991) - et al.
Primary sclerosing cholangitis: refinement and validation of survival models
Gastroenterology
(1992) - et al.
Sclerosing cholangitis in ulcerative colitis. A follow-up study
Scand J Gastroenterol
(1982) - et al.
Outcome of PSC. Analysis of long-term observation of 38 patients
Arch Intern Med
(1987) - et al.
Primary sclerosing cholangitis. A long-term follow-up study
Scand J Gastroenterol
(1987) - et al.
Primary sclerosing cholangitis: natural history, prognostic factors, and survival
Hepatology
(1989) - et al.
Does PSC occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects
Hepatology
(1990) - et al.
Sclerosing cholangitis in ulcerative colitis
Scand J Gastroenterol
(1980)
Cited by (105)
Current trends and future perspectives in the treatment of PBC and PSC: A review
2022, Health Sciences ReviewRisk factors for chronic inflammatory disorders of ileal pouch
2018, Pouchitis and Ileal Pouch Disorders: A Multidisciplinary Approach for Diagnosis and ManagementThe impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis
2014, Digestive and Liver DiseaseCitation Excerpt :Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by destruction of the bile ducts and a high risk for progression to liver cirrhosis and cholangiocarcinoma [1,2].
Geoepidemiology of primary sclerosing cholangitis: A critical review
2013, Journal of AutoimmunityA unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease
2012, Journal of Crohn's and ColitisCitation Excerpt :If these patients had been included as CD, this would bias data towards a milder disease phenotype. Nevertheless, it should be noted that despite the strict definition of CD applied, 13.3% of the Oxford PSC population had concomitant CD, which falls in the upper range of previously reported prevalence data.9 This study suggests a better prognosis in patients with PSC/CD compared to those with PSC/UC, with a significant difference in major event-free survival (cancer, liver transplantation or death) observed, (p = 0.04).
Primary sclerosing cholangitis
2018, The LancetCitation Excerpt :With a prevalence of less than 50 per 100 000, primary sclerosing cholangitis meets the criteria for a rare disease, which brings advantages in drug development through eligibility for orphan status (unless the drug is approved for a more common disease). Primary sclerosing cholangitis is more common in men (65–70%)24,28 and is most often diagnosed between the ages of 30 and 40 years.24,28,29 In a population-based primary sclerosing cholangitis study24 from the Netherlands, the median survival from diagnosis until liver transplantation or primary sclerosing cholangitis-related death was 21·3 years compared with survival in a combined transplant centres primary sclerosing cholangitis cohort of 13·2 years (p<0·0001).24